- Cancer Biology & Biomarkers
- Chromatography & Mass Spectrometry
- Contract Research, Clinical Trials and Outsourcing
- Drug Discovery
- Drug Targets
- Flow Cytometry
- Informatics & Lab Automation
- Ingredients, Excipients and Dosages
- Microbiology & RMMs
- NIR, PAT & QbD
- Raman Spectroscopy
- Screening, Assays & High-Content Analysis
- Thermal Processing
- Events & Workshops
New data show clinical benefit of Adacolumn in UC
24 May 2016 • Author: Victoria White, Digital Content Producer
New data has been presented for Otsuka’s Adacolumn in patients with ulcerative colitis (UC).
Data from the 48-week ART trial showed that remission and response rates were 37.2% and 53.2% respectively at week 12, in patients with moderate-to-severe, steroid-dependent active UC with insufficient response or intolerance to immunosuppressants and / or biologics when treated with between five and eight sessions with Adacolumn.
Adacolumn is a non-pharmacological treatment which reduces inflammation by removing white blood cells from the blood circulation. This reduces the inflammatory burden without the risk of side effects attributed to drugs in patients with inflammatory bowel disease (IBD), such as active UC.
UC is associated with an imbalance of leukocytes, which play a key role in inflammation. In UC, these inflammatory cells migrate into the intestinal mucosa at twice the normal levels causing mucosal inflammation. Targeting leukocytes or their communication is the rationale behind most IBD treatments.
Adacolumn may be an alternative to elective surgery
Commenting on the new data, Prof. Dr. Axel Dignass, Agaplesion Markus Hospital, Frankfurt, Germany, said: “Ulcerative colitis is a debilitating disease with increasing prevalence and affects many young people. Ultimately, the goal of our treatment is to induce steroid-free clinical remission. However, patients with moderate to severe ulcerative colitis and their healthcare professionals are faced with many hard choices, particularly when it comes to choosing the best treatment, since many have side effects that severely impact quality of life and may even be life-threatening.
“The ART data have shown that there is an alternative for this difficult-to-treat population with a favourable safety profile that can delay the need for irreversible surgery. In addition, it is important to note that colectomy rates were comparable to those seen in anti-TNFs trials with stricter selection criteria. This shows that Adacolumn may be an alternative to elective surgery when compared to anti-TNFs in a less-selected population.”
Prof. Dr. Dignass added: “Ultimately, these data show that Adacolumn provided clinical benefit in a large cohort of steroid-dependent patients with ulcerative colitis with previous failure to biologics.”
ABB Analytical Measurement ACD/Labs ADInstruments Ltd Advanced Analytical Technologies GmbH Analytik Jena AG Astell Scientific Ltd B&W Tek Bachem AG Bibby Scientific Limited Bio-Rad Laboratories BioNavis Ltd Biopharma Group Black Swan Analysis Limited Charles Ischi AG | Kraemer Elektronik Cherwell Laboratories CI Precision Cobalt Light Systems Coulter Partners CPC Biotech srl Dassault Systèmes BIOVIA DiscoverX Edinburgh Instruments Enterprise System Partners (ESP) EUROGENTEC F.P.S. Food and Pharma Systems Srl IDBS JEOL Europe L.B. Bohle Maschinen + Verfahren GmbH Lab M Ltd. LabWare Linkam Scientific Instruments Limited Molins Technologies Multicore Dynamics Ltd Nanosurf New England Biolabs, Inc. Panasonic Biomedical Sales Europe B.V. PerkinElmer Inc ReAgent Russell Finex Limited Source BioScience Takara Clontech Tornado Spectral Systems Tuttnauer Watson-Marlow Fluid Technology Group Wickham Laboratories Limited Xylem Analytics YMC Europe GmbH Yusen Logistics